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See related article on page 928. In 1965 Sodi-Pollares and colleagues1 first used glucose-insulin-potassium(GIK) solutions to treat patients with acute myocardial infarctions andfound that this limited infarct size, reduced ventricular ectopy, and im-proved survival. Early studies in isolated heart preparations with regionalischemia showed that GIK decreased infarct size, increased high-energyphosphate levels, and improved ventricular function.2 Clinical studies in
patients with acute myocardial infarction demonstrated that GIK enhanced myocar-
dial performance.3 However, enthusiasm for GIK was dampened by a British
Medical Research Council clinical trial of patients with acute myocardial infarction
that failed to show any survival benefit with GIK therapy.4 In that study, GIK
protocols were inconsistent, such that different doses and volumes of GIK were
administered at various times from the onset of the infarct, making it difficult to
determine the effectiveness of GIK therapy. The role of glucose and insulin in
cardiac surgery was further diminished by the introduction of cold chemical car-
dioplegia and hypothermic cardiopulmonary bypass because of the inhibitory effects
of hypothermia on glucose and insulin metabolism. However, the increased numbers
of patients requiring urgent coronary artery bypass grafting (CABG) for acute
coronary syndromes, many with reduced ventricular function, and the introduction
of warm cardioplegia and cardiopulmonary bypass techniques have prompted a
renewed interest in substrate enhancement with glucose and insulin in an attempt to
augment myocardial protection and improve clinical outcomes for these high-risk
patients.
There are several mechanisms by which glucose and insulin protect the ischemic
myocardium. Although the primary energy source for the nonischemic myocardium
is free fatty acids, glucose is the preferred substrate during periods of ischemia.
Adenosine triphosphate derived from glycolysis is vital for stabilization of mem-
brane ion transport, which in turn is crucial to the cellular integrity of myocytes,
endothelium, and vascular smooth muscle cells. Preservation of coronary endothe-
lial function during cardioplegic arrest has been shown to decrease ischemic
necrosis.5 Glucose also esterifies intracellular free fatty acids, which decreases their
toxic end-products, oxygen free radicals. Because glucose is a direct precursor of
pyruvate, which is carboxylated to the citric acid cycle substrates malate and
oxaloacetate, it can replenish depleted postischemic substrates, thus stimulating
oxidative metabolism. Experimental studies have shown that glucose converted to
pyruvate can restore contractile function through the replenishment of depleted
citric acid substrates.6
Insulin benefits the postischemic myocardium by stimulating pyruvate dehydro-
genase activity, which stimulates aerobic metabolism on reperfusion. Exogenous
insulin helps to reverse insulin resistance during cardiopulmonary bypass, which
contributes to increased serum concentrations of free fatty acids and decreased
myocardial uptake of glucose. Intravenous infusions of insulin after CABG have
been shown to decrease the levels of free fatty acids and increase myocardial uptake
of glucose.7 Insulin added to antegrade and retrograde tepid (29°C) blood cardio-
plegia has been shown to stimulate aerobic metabolism during reperfusion, prevent-
ing lactate release and improving left ventricular stroke work index.8 Insulin is
especially beneficial for patients with diabetes and acute coronary ischemia. Patients
with diabetes are characterized by impaired glucose uptake and increased plasma
levels of free fatty acids during ischemia, which leads to arrhythmias and depressed
myocardial performance. Insulin enhances myocardial glucose utilization and de-
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creases free fatty acid levels in these patients. Diabetic
coronary vessels tend to be prone toward vasoconstriction
as a result of endothelial dysfunction resulting in decreased
prostacyclin and nitric oxide production and higher levels of
endothelin-1.9 Insulin upwardly regulates the L-arginine-
nitric oxide pathway, which results in decreased vascular
resistance and contributes to improved myocardial perfor-
mance on reperfusion. Patients with diabetes have impaired
platelet function, resulting in increased platelet aggregabil-
ity, which predisposes them toward coronary thrombosis.
Insulin improves platelet function and decreases plasma
activity of plasminogen activator, which is increased in
patients with diabetes.10
The rationale for using GIK therapy during the revascu-
larization of acutely ischemic myocardium is based on the
premise that during ischemia exogenous glucose provides
increased adenosine triphosphate through glycolysis, which
maintains cell viability. On reperfusion, both glucose and
insulin replenish citric acid cycle substrates, which promote
high-energy phosphorylation. Experimental and clinical
studies have shown that substrate enhancement with GIK is
most effective when periods of ischemia are followed by
reperfusion.11,12 On the basis of these facts, my group rea-
soned that GIK might play an important role during the
surgical revascularization of acutely ischemic myocardium.
In an experimental study with a porcine model of acute
coronary ischemia and reperfusion on cardiopulmonary by-
pass with cardioplegic arrest, hearts treated with GIK had a
significant decrease in the incidence of ventricular arrhyth-
mias, less tissue acidosis, better preservation of wall motion,
and the lowest area of myocardial necrosis.13 Animals that
received GIK during both the periods of ischemia and
reperfusion did significantly better than did those receiving
GIK during reperfusion only. These favorable results
prompted us to perform a clinical study in which GIK was
initiated during anesthetic induction and continued for 12
hours after the operation in patients who required urgent and
emergency CABG.14 Patients who received GIK had higher
cardiac indices, a decreased need for inotropic support, less
weight gain, faster extubation times, a significantly lower
incidence of atrial fibrillation, and shorter intensive care unit
and hospital stays. Similar results were seen in a group of
patients with diabetes undergoing CABG who received a
modified GIK solution.15
In view of these favorable effects of glucose and insulin
during CABG, how can we explain the results of the Insulin
Cardioplegia Trial reported by Rao and coauthors16 in this
issue of the Journal, in which they failed to demonstrate any
clinical benefit from insulin-enhanced cardioplegia for high-
risk patients undergoing isolated CABG? There are several
flaws in the design of the study. A number of variables were
not controlled for, including the temperature and route of
delivery of the cardioplegia solutions and the amount of
intravenous insulin used to control blood glucose levels in
the placebo group. In fact, the placebo group received
almost as much insulin as did the insulin cardioplegia group.
Although the authors were quick to point out that subgroup
analyses could find no differences between the groups when
these variables were controlled for, it adds an element of
bias that should not have to be addressed in such an impor-
tant study. The major end points of the study, the develop-
ment of myocardial infarction according to enzyme criteria
and low output syndrome, are weak. Modern evaluation of
outcomes after CABG should include the need for inotropic
support, development of ventricular and atrial arrhythmias,
weight gain, length of ventilatory support, infections (espe-
cially in patients with diabetes), and intensive care unit and
postoperative hospital stays. It is not just the rate of enzyme
leakage, which is unlikely to have major clinical importance
in the absence of electrocardiographic or echocardiographic
changes, but how completely and rapidly patients recover
from CABG that is most important in assessing clinical
outcome in today’s health care system.
Despite these shortcomings, I agree with the Rao and
coauthors’ conclusions that the administration of insulin
during a short period of cardioplegic arrest has no mean-
ingful impact on clinical outcomes. However, I disagree
with their premise that myocardial protection may not be as
important as technical considerations in improving clinical
outcomes for these high-risk patients. To me, the main
message of this study is that our strategies for myocardial
protection should not be limited to the traditional period of
cardioplegic arrest but must be expanded to include other
potential periods of ischemia. These include the time from
anesthetic induction to the initiation of cardiopulmonary
bypass and the period of reperfusion after aortic unclamp-
ing. This is why our clinical studies with GIK were so
effective in improving clinical outcomes.
It would be wrong to discount the benefits of glucose and
insulin for patients undergoing CABG on the basis of this
study. If we are to improve clinical outcomes for these
high-risk patients, we must not attempt to concentrate met-
abolic substrate enhancement only during a short period of
cardioplegic arrest. As our concept of myocardial protection
widens from the traditional period of cardioplegic arrest to
include the pre–cardiopulmonary bypass and post–cardio-
pulmonary bypass periods, GIK will emerge as a safe,
inexpensive, and effective therapeutic intervention in im-
proving clinical outcomes for all our patients undergoing
CABG.
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